ASX Release
21 January 2025

ASX code: PIQ

Quarterly Activities Report

Proteomics International Laboratories Ltd (Proteomics International; the Company; ASX: PIQ), a pioneer in precision diagnostics is pleased to provide the following update on its business activities for the three months to 31 December 2024.

- **Breakthrough results for endometriosis diagnostic blood test:** Plasma protein biomarker panel identifies all stages of endometriosis with high accuracy, with results published in the prestigious medical journal *Human Reproduction*.
- **PromarkerD results for predicting kidney decline in type 1 diabetes published:** Far-reaching results published in the peer-reviewed journal of *Clinical Diabetes and Endocrinology* show PromarkerD demonstrated high accuracy in predicting chronic kidney disease in patients with type 1 diabetes.
- **Novel OxiDx test detects muscle damage in elite athletes:** World-first results demonstrate the OxiDx test can identify and assess recovery from intense exercise in elite marathon runners.
- **R&D tax incentive funding:** Company's cash reserves further strengthened by $2.16 million government rebate
- **KOL and consumer engagement plus PIQ in the media**
- **Financial and Corporate Highlights:** Dr James Williams becomes Chair, appointment of Aaron Brinkworth to the Board as independent, non-executive Director, while new Chief Commercial Officer and Clinical Pathologist join the management team.

The Company is also pleased to provide guidance on its activities in key areas for the second half of FY25.

- **Next steps in commercialisation:**
  - **Promarker®D**
  - **Promarker®Endo**
  - **Promarker®Eso**
  - **OxiDx**
- **Target milestones and share price catalysts FY25**

OPERATIONAL HIGHLIGHTS – ENABLING PRECISION MEDICINE

Proteomics International's activities fall into three strategic areas:

I. Commercialisation of the Company's pipeline of precision diagnostics
II. Precision diagnostic tests in development
III. Specialist accredited analytical services on a commercial basis

Proteomics International is at the forefront of predictive diagnostics and precision medicine. The Company now has a suite of diagnostic tests entering commercialisation, with the PromarkerD, PromarkerEndo, PromarkerEso and OxiDx tests each passing pivotal points in their advancement.

Go-to-Market pathways for the Company's suite of novel diagnostic tests

To achieve revenue from its diagnostic tests Proteomics International is targeting synergistic Go-to-Market models, namely Direct to Consumer/Patient (DTC/DTP) and digital marketing, alongside traditional licensing, as shown below.

Advances in digital health and direct-to-consumer healthcare, driven by essential changes in medical practice due to the global pandemic and evolution of social and digital media, are transforming previously expensive and low volume routes to market for diagnostic testing into cost-effective and exciting opportunities, which sit alongside traditional licensing models. The Company is engaged with multiple partners across all aspects of the supply/provider chain to accelerate the commercial roll-out of its tests.

Direct to consumer/patient (DTC/DTP) and digital marketing pathway



PRECISION DIAGNOSTIC TESTS – THE PROMARKER® PIPELINE

Proteomics International develops novel precision health and predictive diagnostic tests using its proprietary biomarker discovery platform called Promarker®. This disruptive technology searches for protein 'fingerprints' in a sample and can identify protein biomarkers that distinguish between people who have a disease and people who do not, using only a simple blood test. It is a powerful advancement on genetic testing. The technology is so versatile it can be used to identify fingerprints from any biological source, from wheat seeds to human plasma. The Promarker® platform technology has broad applicability and is being used to produce multiple new diagnostic tests to address significant unmet medical and commercial needs.

Promarker®D – predicting diabetic kidney disease

PromarkerD is a cutting-edge diagnostic test specifically designed to predict the risk of diabetic kidney disease (DKD) in individuals with diabetes. It provides a significant advancement in diabetes management by enabling early detection and intervention, which are crucial for preventing or delaying the progression of this serious complication to end stage renal disease (dialysis or kidney transplant).

PromarkerD results for predicting kidney decline in type 1 diabetes published in peer-reviewed journal
[ASX: 11 October] Proteomics International announced the publication of far-reaching results showing the PromarkerD predictive test can predict renal decline in type 1 diabetes. The results were published in the peer-reviewed journal of *Clinical Diabetes and Endocrinology*[1] having been first presented at the Australasian Diabetes Conference in Perth, Australia, in August [ASX: 23 August].

The study addressed a significant gap in the medical field, focusing on the lack of prognostic biomarkers for chronic kidney disease (CKD) in individuals with type 1 diabetes. Utilising the PromarkerD test, originally developed and validated for predicting renal decline in type 2 diabetes, the study of 92 community-based individuals demonstrated outstanding performance in predicting CKD risk and kidney function decline. These preliminary findings suggest that the PromarkerD test is a highly effective prognostic tool for renal decline in both type 1 and type 2 diabetes, heralding a new era in diabetic kidney disease management.

Diabetes affects over 537 million people worldwide, and chronic kidney disease is a major complication, leading to severe health outcomes and increased mortality. Type 1 diabetes represents approximately 10% of all cases of diabetes and cannot be prevented[2]. Diabetes has emerged as the largest single cause of end stage renal disease (leading to dialysis or kidney transplant) in developed and developing countries.

Proteomics International is pursuing multiple avenues to ensure its novel blood test for predicting diabetic kidney disease can be launched in key markets via its hybrid Go-to-Market strategy,

Promarker®D next steps:

- Automated PromarkerD immunoassay is operational in Proteomics International's Perth laboratory with the Company applying for ISO 15189 accreditation to enable it to offer the test to patients
- Target launch date for PromarkerD in Australia of Q1 CY25
- Proteomics International is establishing a reference laboratory in the USA to run PromarkerD with the Company applying for CLIA certification to enable it to offer the test to patients in the USA
- Target launch date for PromarkerD in USA of H1 CY25
- Continuing to build awareness of the test with clinicians, key opinion leaders (KOL's) and patient advocacy groups
- Progressing direct-to-consumer/patient (DTC/P) process, building a framework of partners to service the digital health provision of PromarkerD (which will also be used for the PromarkerEndo and PromarkerEso tests)
- Partnering discussions ongoing for traditional licensing Go-to-Market route

Further information about Promarker®D is available through the web portal (www.PromarkerD.com)

To visit the PromarkerD virtual product display please see: www.PromarkerD.com/product

Promarker®Endo – diagnosing endometriosis

Endometriosis is a common disease that affects approximately one in nine women and girls, often starting in teenagers. It can cause pelvic pain, painful periods and infertility, and costs Australia alone $9.7 billion each year[3] (see also PIQ Annual Report 2024). Currently, there is no simple way to test for endometriosis, which takes an average of seven years to diagnose due to the reliance on invasive laparoscopy. Endometriosis occurs when tissue similar to the lining of the uterus grows in other parts of the body where it does not belong.

[1] clindiabetesendo.biomedcentral.com/articles/10.1186/s40842-024-00191-8
[2] International Diabetes Federation 2021

Breakthrough results for diagnosing all stages of endometriosis published in peer-reviewed journal
[ASX: 30 December] Proteomics International published pivotal new results in the prestigious medical journal *Human Reproduction* showing its PromarkerEndo blood test can diagnose all stages of endometriosis with high accuracy. The new study has identified a breakthrough: a novel panel of 10 plasma protein biomarkers that could revolutionise the diagnosis of this debilitating disease.

Proteomics International scientists, in collaboration with the Royal Women's Hospital and the University of Melbourne, analysed plasma samples from 805 participants across two independent clinical populations, comparing cases of endometriosis, general population controls, and symptomatic controls. Using advanced proteomics and statistical modelling, three diagnostic models were developed. The standout, Model 3, distinguished severe endometriosis from symptomatic controls with near-perfect accuracy. It also showed excellent diagnostic performance across earlier disease stages.

Proteomics International is pursuing multiple avenues to ensure its novel blood test for endometriosis is commercial ready via its hybrid Go-to-Market strategy, with a target launch date of Q2 CY25 in Australia, with other jurisdictions to follow.

Promarker®Endo next steps:

- Analytical methodology is being adapted for use in a clinical environment
- Diagnostic algorithm is being refined using 'traffic light' system to further improve test performance for clinical use
- Clinical validation study on cohort of samples from the University of Oxford [ASX: 25 March 2024] is ongoing and subject to completion of the adapted method for clinical use
- Discussions are advancing in key markets for licensing in women's health and fertility
- Continuing to build awareness of the test with clinicians, key opinion leaders (KOL's) and advocacy groups in response to the upsurge in demand for better diagnosis of endometriosis
- Patents pending in all major jurisdictions
- Proteomics International preparing to launch PromarkerEndo in Australia, targeting Q2 CY25

Promarker®Eso – diagnosing esophageal cancer

Esophageal adenocarcinoma (EAC) is the most common form of esophageal cancer and an area of significant unmet medical need, with 1 in 20 cancer deaths worldwide in 2018 attributed to esophageal cancer[4]. The five-year survival rate for EAC is less than 20% because it is frequently diagnosed too late for effective treatment.

Men over 50 with a history of obesity face elevated risk of EAC, alongside risk factors such as chronic acid reflux, also known as gastroesophageal reflux disease (GERD). Barrett's Esophagus is the only known precursor to EAC, however, 95% of people with Barrett's Esophagus never develop EAC and 95% of patients diagnosed with EAC have no preceding diagnosis of Barrett's Esophagus[5].

Current gold-standard screening for the disease requires a specialist endoscopy, an invasive procedure that costs between £1,000-2,000 in the UK[6], and US$2,750 in the United States[7] where total expenditure on treating EAC was US$2.9 billion in 2018. In the US 1.5 million endoscopies with biopsy are performed annually in individuals with chronic acid reflux symptoms, but despite this up to 90% of EAC cases continue to go undetected[8].

The Company is pursuing multiple avenues to ensure its novel blood test for esophageal cancer is commercial ready via its hybrid Go-to-Market strategy, with a target launch date of Q1 CY25 in Australia, with other jurisdictions to follow.

[4] Nature Reviews Gastroenterology & Hepatology, 2021, doi.org/10.1038/s41575-021-00419-3
[5] www.cancer.org.au/assets/pdf/9-august-2020
[6] digestivehealthyuk.com/test/endoscopy-gastroscopy/answerpack/endoscopy-faq/how-much-does-an-endoscopy-cost/
[7] www.newchoicehealth.com/endoscopy/cost
[8] Gastroenterology. 2022 Jul; 163(1): 163‐173; doi: 10.1053/j.gastro.2022.03.037

Promarker®Eso next steps:

- PromarkerEso showed 94% accuracy in diagnosing patients with and without the disease in a clinical validation study (presented at World Congress Esophageal Diseases 2024) [ASX: 23 September]
- Diagnostic algorithm refined using 'traffic light' system to improve test performance for clinical use
- Analytical methodology is being prepared for use in a clinical environment with the Company applying for ISO 15189 accreditation to enable it to offer the test to patients in Australia
- Partnering discussions are underway
- Patents granted in Europe, China, Australia; USA pending
- Proteomics International preparing to launch PromarkerEso in Australia, targeting Q1 CY25

OxiDx – diagnosing muscle damage

Oxidative stress occurs when the body's antioxidant defences are overwhelmed by an excess of toxic oxidants, often referred to as free radicals. Oxidative stress is implicated in over 70 health conditions, with levels often reflective of a person's health condition[9].

OxiDx test detects muscle damage in elite athletes - groundbreaking results published

[ASX: 31 December] OxiDx Pty Ltd (OxiDx), a subsidiary of Proteomics International, published world-first results in the peer-reviewed journal *Physiological Reports*[10] demonstrating the unique OxiDx test for oxidative stress can identify lurking muscle damage and then assess recovery in elite marathon runners.

The study addresses a significant gap in the field of sports science, focusing on the lack of sensitive biomarkers for exercise-induced muscle damage. In professional sports, muscle injuries are the most frequent cause of incapacity, accounting for up to 55% of all injuries. Similarly, in the horse racing industry, 85% of thoroughbreds suffer at least one injury during their first 2-3 years of their racing career[11]. In 2023, $1.2 billion was spent on treating potentially avoidable sports injuries in Australia[12].

The results are a significant milestone proving the OxiDx test can be used to monitor athletic performance and could literally be a game changer for sports medicine, with this easy-to-use finger-prick test able to detect unseen muscle damage, allowing athletes to adjust their training regime to avoid more serious injury.

OxiDx next steps:

- Groundbreaking results demonstrate the OxiDx test can identify and assess recovery from exercise-induced muscle damage in elite marathon runners
- Proof of conduct study underway to confirm the ability of the OxiDx test to predict muscle damage in racehorses
- Patents granted in USA, Australia, Japan and Europe
- Proteomics International aims to launch the new test in Australia through its OxiDx subsidiary in mid 2025.

ANALYTICAL SERVICES

The demand for analytical services remains steady, covering the areas of pharmacokinetic testing, biosimilars and proteomics analysis, food testing, and biomarker discovery on a contract basis. The Company continues to look for opportunities to grow these revenues, targeting the clinical trials sector for both pharmacokinetic testing and the development of companion/complementary diagnostics (CDx) through biomarker analysis.

[9] Doi: 10.1373/clinchem.2005.061408
[10] Physiological Reports: doi.org/10.14814/phy2.70155
[11] Appraising the Welfare of Thoroughbred Racehorses in Training in Queensland
[12] Australian Institute of Health and Welfare (2023): Economics of sports and physical activity participation and injury

EVENTS AND MARKETING

The Company's Managing Director Dr Richard Lipscombe was an invited speaker at the international conference "Advancing Multi-Omics into the Clinic" in Sydney, Australia (18-19 November), which showcased the Company's world leading portfolio of diagnostic tests, while an e-poster highlighting Proteomics International's far-reaching results for the PromarkerD test in people with type 1 diabetes was presented at the American Society of Nephrology's Kidney Week 2024 in San Diago, California (24-27 October).

The Company was also represented at the Royal Australian College of General Practitioners (RACGP) Annual Conference in Perth, Australia (21-23 November), Medica 2024 in Düsseldorf, Germany (11-14 November), AusBiotech 2024 in Melbourne, Australia (30 Oct-1 Nov) and the Annual Academic Surgery Conference in Adelaide, Australia (15-16 November).

For investor engagement, Proteomics International was invited to present at the Bell Potter Healthcare Conference 2024 (November 18-20), a virtual event showcasing Australia's best healthcare companies [ASX: 20 November].

All PIQ announcements and related shareholder information are available from the Company's website[13].

Proteomics International in the media

Following the recent peer-reviewed publication of the PromarkerEndo and OxiDx results, the tests have received widespread media coverage including from Channel 7 News, Channel 9 News, The Australian, Sky News Australia, RACGP, 6PR and TVNZ[14]**.**

Forthcoming Events

During the next quarters, Proteomics International will be represented at the following events and conferences:

- **BioAsia**; 24-26 February, Hyderabad, India
- **Australian Gynaecological Endoscopy & Surgery (AGES) Annual Scientific Meeting**; 27 February-1 March, Perth, Western Australia
- **National Kidney Foundation (USA)**; 7-10 April, Boston, USA
- **World Congress of Endometriosis**; 21-24 May, Sydney, Australia

These events align with the Company's objective of actively engaging with potential users of its technology to foster awareness, adoption and uptake of its novel diagnostic tests.

FINANCIAL AND CORPORATE HIGHLIGHTS

Proteomics International's business model is to commercialise its pipeline of novel diagnostic tests, exemplified by PromarkerD, PromarkerEndo, PromarkerEso and OxiDx, in major markets across the world, and offset the cash burn from R&D and product development through its analytical services revenue, coupled with the R&D tax incentive rebate. This diversified model enables the group to make optimum use of its resources.

Operations

Proteomics International continued its process of recruiting the additional Board and Management skills and experience necessary to support acceleration of its commercialisation initiatives.

[ASX: 30 October] Proteomics International announced that non-executive director James Williams became Chair following the Company's AGM, with Neville Gardiner standing down from the role and continuing as a non-executive director.

Proteomics International also announced the appointment of Aaron Brinkworth to its Board as independent,

[13] www.proteomics.com.au/investors/ investors/asx/

[14] www.proteomics.com.au/newsroom/inthemedia/news-media/

non-executive Director, in concert with the retirement of Roger Moore as non-executive Director, effective November 8, 2024.

Mr Brinkworth is a former biopharmaceutical executive with 25 years industry experience and has held senior commercial, patient access and strategic licensing roles. Mr Brinkworth currently serves as non-executive Director for Resonance Health Ltd (ASX: RHT). He is a graduate of the AICD Company Directors course and maintains active membership of the AICD.

The senior management team was bolstered by the appointment of Phillip Pather as new Chief Commercial Officer (CCO) and Dr Johan Conradie as Clinical Pathologist.

As CCO, Mr Prather is responsible for global sales, marketing, and customer engagement activities, and brings extensive leadership in the global medical devices industry, particularly in developing new markets and successfully launching products for innovative companies including Cochlear, QIAGEN, Philips, and Medtronic.

Dr Conradie, a Chemical Pathologist with over 21 years of experience, specialises in clinical biochemistry and toxicology across South Africa and Australia. With qualifications including FCPath, FRCPA, and an MBA, Dr Conradie supports Proteomics International's clinical accreditation (ISO 15189) processes and will oversee the Company's testing of patient samples. Dr Conradie also serves as Medical Director for Western Diagnostic Pathology.

Proteomics International Receives $2.16 million in R&D Tax Incentive

[ASX: 16 December] Proteomics International's cash reserves were further strengthened by the receipt of $2.16 million in research and development tax incentive for the 2023-24 financial year, after the Company spent $4.95 million on R&D during the period.

The funding is being used to support key milestones:

1. The establishment of the Proteomics International USA Inc laboratory and its CLIA accreditation for performing Laboratory Developed Tests (LDTs);
2. Clinical certification (ISO 15189) of Proteomics International's Perth laboratory to enable testing of clinical samples; and
3. Subsequent launch of the PromarkerD (Q1 CY25), PromarkerEso (Q1 CY25) and PromarkerEndo (Q2 CY25) tests in Australia.

Revenue & Expenditure

Proteomics International achieved cash receipts from customers for the December quarter of $285,000 (September quarter: $253,000). The net operating cash inflow for the December quarter was $246,000 (cash outflow in September quarter: $1.46 million). Expenditure centred on the following areas:

- Business development and commercialisation costs for the rollout of PromarkerD
- Acceleration of the Go-to-Market strategies for PromarkerEndo and PromarkerEso
- R&D for projects in the Promarker® diagnostics pipeline, led by PromarkerEndo, PromarkerEso and OxiDx

ASX Listing Rule 4.7C

Payments at item 6.1 of Appendix 4C of $163,000 relate to normal remuneration of Executive and Non-Executive Directors.

Cash Position

At 31 December, the Company had cash reserves of $5.33 million (30 September: $5.10 million).

TARGET MILESTONES FY25

Proteomics International is anticipating multiple potential share price catalysts during FY25 as shown below:

Milestone	TARGET Qtr Dec	Mar	Jun	Impact
Commercial				
US reference lab established		■		Key to first US sales and reimbursement
First Sales PromarkerD in USA		■	■	Initiate pathway to significant revenues
Australian clinical lab certification established		■		
PromarkerD launched in Australia/EU		■		Drive global uptake and future revenue
PromarkerEndo launched in Australia			■	First sales
PromarkerEso launched in Australia		■		First sales
Clinical/Technical				
Endometriosis Dx - results update	✓			New first-in-class diagnostic test
Esophageal Cancer Dx - results update	✓			New first-in-class diagnostic test
OxiDx test - results update	✓			New first-in-class diagnostic test

Authorised by the Board of Proteomics International Laboratories Ltd (ASX: PIQ).

ENDS

About Proteomics International Laboratories (PILL) (www.proteomicsinternational.com)
Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of precision diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.

For further information please contact:

Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com

Dirk van Dissel
Investor Relations
Candour Advisory
T: +61 408 326 367
E: dirk@candouradvisory.com.au

Proteomics International (Europe)
Plesmanweg 9, 7602 PD Almelo
The Netherlands
T: +31 85 40 11 173
E: Europe@PromarkerD.eu

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Name of entity	
Proteomics International Laboratories Ltd	
ABN	**Quarter ending ("current quarter")**
78 169 979 971	**31 December 2024**

Consolidated statement of cash flows		**Current Quarter $A'000**	**Year to date $A'000**
1.	**Cash flows related to operating activities**		
1.1	Receipts from Customers	285	538
1.2	Payments for		
	(a) research & development	(1,139)	(2,146)
	(b) product manufacturing & operating costs	(235)	(379)
	(c) advertising & marketing	(168)	(213)
	(d) leased assets	0	0
	(e) staff costs	(610)	(1,080)
	(f) administration & corporate costs	(156)	(432)
1.3	Dividends received (see note 3)	0	0
1.4	Interest received	62	161
1.5	Interest & other costs of finance paid	(16)	(16)
1.6	Income taxes paid	0	0
1.7	Government grants & tax incentives	2,223	2,358
1.8	Other (provide details if material)	0	0
1.9	**Net cash from / (used in) operating activities**	**246**	**(1,209)**
2.	**Cash flows related to investing activities**		
2.1	Payments to acquire:		
	(a) entities	0	0
	(b) businesses (see item 10)	0	0
	(c) property, plant & equipment	(5)	(21)
	(d) investments	0	0
	(e) intellectual property	0	0
	(f) other non-current assets	0	0
2.2	Proceeds from disposal of:	0	0
	(a) entities	0	0
	(b) businessess (see item 10)	0	0
	(c) property, plant & equipment	0	0
	(d) investments	0	0
	(e) intellectual property	0	0
	(f) other non-current assets	0	0
2.3	Cash flows from loans to other entities	0	0
2.4	Dividends received (see note 3)	0	0
2.5	Other (provide details if material)	0	0
2.6	**Net cash from / (used in) investing activities**	**(5)**	**(21)**

Consolidated statement of cash flows		Current Quarter $A'000	Year to date $A'000
3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	0	0
3.2	Proceeds from issue of convertible debt securities	0	0
3.3	Proceeds from exercise of options	0	0
3.4	Transaction costs related to issues of equity securities or	0	(2)
	convertible debt securities	0	0
3.5	Proceeds from borrowings	0	0
3.6	Repayment of borrowings	0	0
3.7	Transaction costs related to loans & borrowings	0	0
3.8	Dividends paid	0	0
3.9	Other (provide details if material)	(14)	(84)
3.10	**Net cash from / (used in) financing activities**	**(14)**	**(86)**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash & cash equivalents at beginning of period	5,098	6,641
4.2	Net cash from / (used in) operating activities (see 1.9 above)	246	(1,209)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(5)	(21)
4.4	Net cash from / (used in financing activities (item 3.10 above)	(14)	(86)
4.5	Effect of movement in exchange rates on cash held	0	0
4.6	**Cash & cash equivalents at end of quarter**	**5,325**	**5,325**

5.	**Reconciliation of cash & cash equivalents** *at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts*	**Current Quarter $A'000**	**Previous Quarter $A'000**
5.1	Bank balance	561	470
5.2	Cash deposits	4,764	4,628
5.3	Bank overdrafts	0	0
5.4	Other (provide details)	0	0
5.5	**Cash & cash equivalents at end of quarter (should equal item 4.6 above)**	**5,325**	**5,098**

6.	**Payments to related parties of the entity & their associates**	**Current Quarter $A,000**
6.1	Aggregate amount of payments to related parties and their associates included in item 1	163
6.2	Aggregate amount of payments to related parties and their associates included in item 2	0

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments

Payments at 6.1 relate to normal remuneration of Executive and Non-Executive Directors

7.	**Financing facilities available** *Note: the term "facility" includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	0	0
7.2	Credit standby arrangements	0	0
7.3	Other(please specify)	0	0
7.4	**Total financing facilities**	**0**	**0**
7.5	**Unused financing facilities available at quarter end**		**0**

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

N/A

8.	**Estimated cash outflows for next quarter**		**$A'000**
8.1	Net cash from / (used in) operating activities (see 1.9 above)		246
8.2	Cash and cash equivalents at quarter end (Item 4.6)		5,325
8.3	Unused financing facilities available at quarter end (Item 7.5)		0
8.4	Total available funding (Item 8.2 + Item 8.3)		5,325
8.5	**Estimated quarters of funding available at quarter end (Item 8.4 divided by Item 8.1)**		**NA**

8.6 If Item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer:

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer:

8.6.3 Does the entity expect to be able to continue its operations and to meet it's business objectives and, if so, on what basis?

Answer:

Note: where item 8.5 is less than 2 quarters, all of the questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance Statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 21 January 2025

Authorised by: The Board

(Name the body or officer authorising release - see note 4)

Notes

1. The quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entities activities for the past quarter, how they have been financed and the effect this has had on the cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of AASB 107: Statement of Cash Flows apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee-eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee,you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's Corporate Governance Principles and Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.